Breaking News
Pfizer and BioNTech updated mRNA COVID-19 vaccine for the 2025-2026 season produced strong immune responses, boosting neutralizing antibody levels by at least fourfold in older people and those with underlying medical conditions.
Positive results from Merck’s Phase III STRIDE-13 trial for its Capvaxive vaccine, a pneumococcal 21-valent conjugate vaccine show it has the potential to provide additional protection in individuals 2 through 17 years old.
The U.S. Food and Drug Administration has expanded the approval of recombinant von Willebrand factor, marketed as Vonvendi.
BioTrending
- By Rachel Maier, MS
While traditional vaccines teach the immune system to fight off foreign invaders, inverse vaccines teach the immune system to ignore its own cells — and may completely reverse autoimmune disease.
- By Keith Berman, MPH, MBA
Shortages and recent spikes in egg prices have boosted public awareness that a “bird flu” is devastating domestic poultry flocks across the country. Since its arrival in the U.S. in January 2022, more than 166 million farmed poultry animals have been sacrificed in an attempt to control the spread of H5N1, a highly pathogenic avian influenza A (HPAI) featuring H5 hemagglutinin and N1 neuraminidase surface proteins (H5N1).
- By Ronale Tucker Rhodes, MS
The dire projection of physician shortages in the U.S. could cause major problems for both patients and healthcare facilities. What's being done to fix it?
- By Amy Scanlin, MS
The incidence and prevalence of STIs remain high, and the serious health consequences of contracting one make prevention a national imperative.
Awards
BSTQ is an Industry Award-Winning Journal
Since its debut in 2009, BioSupply Trends Quarterly’s articles have been recognized by some of the industry’s most prominent organizations, earning platinum and gold awards.
